DE60115433D1 - Verfahren zur behandlung von chronischen geschwüren - Google Patents

Verfahren zur behandlung von chronischen geschwüren

Info

Publication number
DE60115433D1
DE60115433D1 DE60115433T DE60115433T DE60115433D1 DE 60115433 D1 DE60115433 D1 DE 60115433D1 DE 60115433 T DE60115433 T DE 60115433T DE 60115433 T DE60115433 T DE 60115433T DE 60115433 D1 DE60115433 D1 DE 60115433D1
Authority
DE
Germany
Prior art keywords
ulcer
matrix
treatment
chronic diseases
oxide inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60115433T
Other languages
English (en)
Other versions
DE60115433T2 (de
Inventor
Anton-Lewis Usala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encelle Inc
Original Assignee
Encelle Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encelle Inc filed Critical Encelle Inc
Application granted granted Critical
Publication of DE60115433D1 publication Critical patent/DE60115433D1/de
Publication of DE60115433T2 publication Critical patent/DE60115433T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/18—Materials or treatment for tissue regeneration for hair reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60115433T 2000-05-31 2001-05-30 Verfahren zur behandlung von chronischen geschwüren Expired - Lifetime DE60115433T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20811600P 2000-05-31 2000-05-31
US208116P 2000-05-31
PCT/US2001/017387 WO2001091774A2 (en) 2000-05-31 2001-05-30 Method of treating chronic ulcers

Publications (2)

Publication Number Publication Date
DE60115433D1 true DE60115433D1 (de) 2006-01-05
DE60115433T2 DE60115433T2 (de) 2006-08-03

Family

ID=22773242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60115433T Expired - Lifetime DE60115433T2 (de) 2000-05-31 2001-05-30 Verfahren zur behandlung von chronischen geschwüren

Country Status (8)

Country Link
US (2) US6992062B2 (de)
EP (1) EP1289537B1 (de)
AT (1) ATE311192T1 (de)
AU (3) AU2001263495B2 (de)
CA (2) CA2410965C (de)
DE (1) DE60115433T2 (de)
NZ (1) NZ523461A (de)
WO (2) WO2001091773A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7828749B2 (en) * 1996-05-17 2010-11-09 Roche Diagnostics Operations, Inc. Blood and interstitial fluid sampling device
MXPA05009803A (es) * 2003-03-13 2006-04-18 Cheryl M Burgess Metodos para administrar un material en un paciente para realce dermico.
JP2005269232A (ja) * 2004-03-18 2005-09-29 Renesas Technology Corp 周波数混合器
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2009137074A1 (en) * 2008-05-06 2009-11-12 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetic ulcers
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2236617A1 (de) * 2009-03-31 2010-10-06 Leukocare Ag Verfahren zur Endsterilisierung von biofunktionalen Zusammensetzungen
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
JP2014532713A (ja) 2011-11-02 2014-12-08 ハルシオン，インコーポレイテッド 創傷処置の方法及び組成物
EP2793963B1 (de) 2011-12-23 2015-11-18 Pioneer Surgical Technology, Inc. Kontinuierliche matrix mit darin dispergierten knochenleitenden teilchen, herstellungsverfahren dafür und verfahren zur knochenregenerierung
JP6816887B2 (ja) * 2015-10-20 2021-01-20 国立大学法人 東京医科歯科大学 発毛促進組成物およびその使用
KR102085404B1 (ko) * 2016-08-31 2020-03-05 주식회사 에스엔비아 부분 비만 치료용 조성물 및 이를 포함하는 마이크로니들
JP2020502087A (ja) 2016-12-21 2020-01-23 ユニリーバー・ナームローゼ・ベンノートシヤープ アミノ酸およびニコチンアミド化合物を含む外用皮膚美白添加物および組成物
CN110325168B (zh) 2016-12-21 2022-10-21 联合利华知识产权控股有限公司 含有胱氨酸的个人护理组合物
CA3046721A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions comprising poorly soluble compounds
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CN112165927B (zh) 2018-05-23 2024-01-30 联合利华知识产权控股有限公司 纳米乳液及其制备方法
CN113679846B (zh) * 2021-08-31 2023-05-09 佛山市第一人民医院（中山大学附属佛山医院） 一种毛发再生剂及其制备方法和应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198479A (en) 1979-03-30 1980-04-15 Merck & Co., Inc. Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4520821A (en) 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US5852009A (en) 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
NO166836C (no) 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
AU589438B2 (en) 1985-08-26 1989-10-12 Hana Biologics, Inc. Transplantable artificial tissue and process
GB8604497D0 (en) 1986-02-24 1986-04-03 Connaught Lab Separation of islets of langerhans
FR2600076A1 (fr) 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
US5079160A (en) 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE68915540T2 (de) 1988-03-09 1994-10-13 Terumo Corp Für zellen eindringbares medizinisches material und kunsthaut.
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
EP0363125A3 (de) 1988-10-03 1990-08-16 Hana Biologics Inc. Produkt, enthaltend vermehrungsfähige Bauchspeicheldrüsen-Endokrinezellen, und Verfahren
US4957902A (en) 1988-12-20 1990-09-18 Board Of Regents, The University Of Texas System Peptide inhibitors of wound contraction
US5059588A (en) * 1989-10-13 1991-10-22 Procyte Corporation, Incorporated Methods and compositions for healing bone using gly his lys: copper
WO1991009119A1 (en) 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5192312A (en) 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
EP0585368B1 (de) 1991-04-25 1997-08-06 Brown University Research Foundation Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1994015589A1 (en) 1992-12-30 1994-07-21 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5358969A (en) 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5246971A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5830492A (en) 1992-02-24 1998-11-03 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
JP3291297B2 (ja) 1992-02-24 2002-06-10 エンセル，インコーポレイテッド 生物人工内分泌装置
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
US5824331A (en) 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
AU3733293A (en) * 1992-02-25 1993-09-13 Alteon Inc. Method and agents for promoting wound healing
US5762959A (en) 1992-05-29 1998-06-09 Vivorx, Inc. Microencapsulation of cells
WO1994003154A1 (en) 1992-07-29 1994-02-17 Washington University Use of pouch for implantation of living cells
US5262055A (en) 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
DE4431598C2 (de) 1993-03-03 1997-03-20 Michael Sittinger Verfahren zum Herstellen eines Implantates aus Zellkulturen
EP0736041B1 (de) 1993-11-17 2006-02-08 Athena Neurosciences, Inc. Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
RU2208636C2 (ru) 1994-01-13 2003-07-20 Дзе Рогозин Институт Макрогранула с секреторными клетками, способ ее получения и способ лечения заболеваний, вызванных нарушением функционирования секреторных клеток
US5487899A (en) * 1994-01-31 1996-01-30 Jess Clarke & Sons, Inc. Wound healing
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
CA2179341A1 (en) 1996-04-12 1997-10-13 Gregory S. Korbutt Methods for isolating, enriching and increasing the maturation of cells
AU725654B2 (en) 1996-05-03 2000-10-19 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5972332A (en) 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
US6458386B1 (en) 1997-06-03 2002-10-01 Innogenetics N.V. Medicaments based on polymers composed of methacrylamide-modified gelatin
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
AU757968B2 (en) * 1998-07-10 2003-03-13 Encelle, Inc. Methods for increasing vascularization and promoting wound healing
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6046160A (en) * 1999-07-22 2000-04-04 Deroyal Industries, Inc. Composition and method for enhancing wound healing
US6491953B1 (en) * 2000-01-07 2002-12-10 Amcol International Corporation Controlled release compositions and method
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins

Also Published As

Publication number Publication date
DE60115433T2 (de) 2006-08-03
WO2001091773A3 (en) 2002-05-02
US20020077277A1 (en) 2002-06-20
AU2001263495B2 (en) 2005-06-02
US7700660B2 (en) 2010-04-20
WO2001091773A2 (en) 2001-12-06
CA2410965C (en) 2010-09-14
AU6349501A (en) 2001-12-11
CA2410965A1 (en) 2001-12-06
CA2410968C (en) 2011-03-29
ATE311192T1 (de) 2005-12-15
US20020065222A1 (en) 2002-05-30
EP1289537A2 (de) 2003-03-12
WO2001091774A2 (en) 2001-12-06
WO2001091774A3 (en) 2002-05-02
NZ523461A (en) 2004-11-26
US6992062B2 (en) 2006-01-31
EP1289537B1 (de) 2005-11-30
AU2001265151A1 (en) 2001-12-11
CA2410968A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DE60115433D1 (de) Verfahren zur behandlung von chronischen geschwüren
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
TW200509956A (en) Compositions and methods for treatment of rosacea
ATE287271T1 (de) Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
AU2001263495A1 (en) Method of treating chronic ulcers
NO994640D0 (no) Hostestillende midler
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
EA200600284A1 (ru) Дооперационное лечение послеоперационной боли
DE69911212D1 (de) Anwendung der hemoproteine in der therapie
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE484293T1 (de) Verfahren zur vorbeugung oder behandlung von diabetes
RU94003799A (ru) Способ лечения псороптозов животных
EP1011672A4 (de) Verbindungen mit analgetischem effekt und zusammenstellungen die diese enthalten
RU93048242A (ru) Способ гляциопунктуры и игла для его осуществления
DE69430807T2 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition